The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker?

Francesco Pantano, Matteo Santoni, Giuseppe Procopio, Mimma Rizzo, Roberto Iacovelli, Camillo Porta, Alessandro Conti, Antonio Lugini, Michele Milella, Luca Galli, Cinzia Ortega, Francesco Maria Guida, Marianna Silletta, Giovanni Schinzari, Elena Verzoni, Daniela Modica, Pierfilippo Crucitti, Annamaria Rauco, Alessandra Felici, Valentina BallatoreStefano Cascinu, Giuseppe Tonini, Giacomo Carteni, Antonio Russo, Daniele Santini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T and C +T raises were significantly associated with baseline BMI (p=0.0412, 0.0283 and 0.0001). Median TTP was significantly longer in patients with T raise compared to patients without T (10 vs 6, p =0.030), C (8 vs 5, p =0.042) and C+T raise (10.9 vs 5.0, p=0.003). At the multivariate analysis, only C+T increase was associated with improved TTP (p=0.005). T raise (21.0 vs 14.0, p=0.002) and C+T increase (21.0 vs 14.0, p=0.006) were correlated with improved OS but were not significant at multivariate analysis. Conclusion: C+T raise is an early predictor for everolimus efficacy for patients with mRCC.

Original languageEnglish
Article numbere0120427
JournalPLoS One
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 17 2015

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker?'. Together they form a unique fingerprint.

Cite this